vTv Therapeutics Inc. (VTVT) |
|
1.74 -0.03 (-1.69%)
|
09-29 09:36 |
|
Open: |
1.77 |
Pre. Close: |
1.77 |
|
High:
|
1.77 |
Low:
|
1.74 |
|
Volume:
|
10,554 |
Market Cap:
|
124M |
|
|
|
|
vTv Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. The company is headquartered in High Point, North Carolina and currently employs 52 full-time employees. The firm is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer's disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial. Its type II diabetes drug candidates include TTP399, an orally administered, liver-selective glucokinase activator (GKA), for which it has completed enrollment in its Phase IIb clinical trial, and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor (GLP-1r), for which it began enrollment in a Phase II clinical trial. The company has over three additional programs in various stages of clinical development for the prevention of muscle weakness and the treatment of inflammatory disorders. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.773 - 1.781 |
1.781 - 1.789 |
|
Low:
|
1.699 - 1.709 |
1.709 - 1.718 |
|
Close:
|
1.754 - 1.77 |
1.77 - 1.785 |
|
Technical analysis |
as of: 2020-09-28 4:38:48 PM |
|
Overall:
|
  |
| Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 2.35  One year: 2.62 |
| Support: |
Support1: 1.65 Support2: 1.37 |
| Resistance: |
Resistance1: 2.01 Resistance2: 2.24 |
| Pivot: |
1.87 |
| Moving Average: |
MA(5): 1.79 MA(20): 1.88
MA(100): 2.40 MA(250): 2.15 |
| MACD: |
MACD(12,26): -0.10 Signal(9): -0.10 |
| Stochastic oscillator: |
%K(14,3): 16.49 %D(3): 20.56 |
| RSI: |
RSI(14): 36.81 |
| 52-week: |
High: 4.23 Low: 1.35 Change(%): 21.2 |
| Average Vol(K): |
3-Month: 51365 10-Days: 62535 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and BEARISH in mid-long term.VTVT has closed above bottom band by 29.4%. Bollinger Bands are 29.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Thu, 24 Sep 2020
vTv Therapeutics Inc. (VTVT) Moves -3.21% Lower: These Numbers are Too Good to be True - News Daemon
Thu, 24 Sep 2020
vTv Therapeutics Inc. (NASDAQ:VTVT) is Waving the Bear Flag - The Oracle Dispatch
Wed, 23 Sep 2020
Why should you add vTv Therapeutics Inc. (VTVT) to your portfolio? - Marketing Sentinel
Wed, 23 Sep 2020
BUZZ-U.S. STOCKS ON THE MOVE-VTv Therapeutics Inc, SPI Energy Co Ltd, Carvana Co, Stich Fix Inc - Nasdaq
Wed, 23 Sep 2020
vTv Therapeutics Presents Additional Positive Clinical Study Results Supporting the Safety and Efficacy of TTP399 as Adjunctive Therapy in Patients with Type 1 Diabetes - GlobeNewswire
Tue, 22 Sep 2020
Is vTv Therapeutics Inc (VTVT) The Right Choice in Biotechnology? - InvestorsObserver
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
|
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
|
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Underperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Underperform |
Price to Earnings: |
Underperform |
| Return on Equity: |
Neutral |
Debt to Equity: |
Underperform |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
48 |
| Shares Float (M) |
13 |
|
% Held by Insiders
|
76.63 |
|
% Held by Institutions
|
1.99 |
|
Shares Short (K)
|
1,900 |
|
Shares Short P. Month (K)
|
1,760 |
Stock Financials |
|
EPS
|
-0.433 |
|
EPS Est This Year
|
-1.060 |
|
EPS Est Next Year
|
-2.250 |
|
Book Value (p.s.)
|
-1.450 |
|
Profit Margin
|
|
|
Operating Margin
|
-98534.78 |
|
Return on Assets (ttm)
|
-143.8 |
|
Return on Equity (ttm)
|
|
|
Qtrly Rev. Growth
|
|
|
Gross Profit (p.s.)
|
-0.258 |
|
Sales Per Share
|
|
|
EBITDA (p.s.)
|
-0.471 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-22 |
|
Levered Free Cash Flow (M)
|
-13 |
Stock Valuations |
|
PE Ratio
|
-4.09 |
|
PEG Ratio
|
|
|
Price to Book value
|
-1.22 |
|
Price to Sales
|
3690.83 |
|
Price to Cash Flow
|
-3.78 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
